A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Status:
Terminated
Trial end date:
2017-09-25
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C
Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in
participants with advanced refractory solid tumors.